About EG BioMed
EG BioMed is a biomedical and healthcare company, and a startup in Taiwan in 2022, that aims to develop new technology for the easy detection of cancer. We develop assessment procedures for cancer screening, monitoring of treatment response, and disease progression.
Core Value
Fast, easy, and accurate.
Rethinking Cancer Treatment.
Importance
In clinical practice, there is a need for novel and objective precise diagnostic methods to improve the accuracy of cancer screening. Developing a highly acceptable and accurate diagnostic method to precisely detect early-stage cancer and provide timely treatment can prevent disease progression to late-stage cancer, which is critical for improving cancer survival rates.
Service Advantage
- No time restrictions
- No fasting required
- Safe and comfortable
- Precise and professional
- Innovative and patented
Innovative Technology
By analyzing big data from the TCGA database, novel DNA methylation biomarkers were identified and validated using the plasma-free DNA of cancer and non-cancer patients. These biomarkers were used to develop an early detection and post-treatment monitoring system for cancer, along with an automated analysis device. In the future, this system is expected to simplify the patient examination process, speed up the time to diagnosis for physicians, increase the regular cancer screening rate among the population, and improve the prognosis of cancer patients.
Awards
• Awarded a patent by the Republic of China in 2021.
• Rewarded with the 2021 18th National Innovation Award by the Institute for Biotechnology and Medicine Industry (IBMI).
• Rewarded with the 2020 Future Tech Breakthrough Award by the Ministry of Science and Technology (MOST).